Evidence map›Paper›PMID 38326029›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2024

Fari Ryan, Isaac Francos-Quijorna, Gerard Hernández-Mir, Catharine Aquino, Ralph Schlapbach, Elizabeth J Bradbury, Samuel David

Open access · hybridAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Fari RyanCentre for Research in Neuroscience and BRaIN Program, Research Institute of the McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada.
Isaac Francos-QuijornaThe Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL, United Kingdom.
Gerard Hernández-MirCentre for Immunobiology, Blizard Institute, Barts and The London School of Medicine, Queen Mary University of London, London E1 2AT, United Kingdom.
Catharine AquinoFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
Ralph SchlapbachFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
Elizabeth J BradburyThe Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL, United Kingdom.ORCID 0000-0003-4252-0234
Samuel DavidCentre for Research in Neuroscience and BRaIN Program, Research Institute of the McGill University Health Centre, Montreal, Quebec H3G 1A4, Canada sam.david@mcgill.ca.
King's College London · GBMcGill University Health Centre · CAUniversity of Zurich · CHQueen Mary University of London · GB

Funding

Medical Research Council MR/R005532/1
6 · The paper itself

Abstract

Toll-like receptors (TLRs) play an important role in the innate immune response after CNS injury. Although TLR4 is one of the best characterized, its role in chronic stages after spinal cord injury (SCI) is not well understood. We examined the role of TLR4 signaling in injury-induced responses at 1 d, 7 d, and 8 weeks after spinal cord contusion injury in adult female TLR4 null and wild-type mice. Analyses include secondary damage, a range of transcriptome and protein analyses of inflammatory, cell death, and extracellular matrix (ECM) molecules, as well as immune cell infiltration and changes in axonal sprouting and locomotor recovery. Lack of TLR4 signaling results in reduced neuronal and myelin loss, reduced activation of NFκB, and decreased expression of inflammatory cytokines and necroptotic cell death pathway at a late time point (8 weeks) after injury. TLR4 null mice also showed reduction of scar-related ECM molecules at 8 weeks after SCI, accompanied by increase in ECM molecules associated with perineuronal nets, increased sprouting of serotonergic fibers, and improved locomotor recovery. These findings reveal novel effects of TLR4 signaling in chronic SCI. We show that TLR4 influences inflammation, cell death, and ECM deposition at late-stage post-injury when secondary injury processes are normally considered to be over. This highlights the potential for late-stage targeting of TLR4 as a potential therapy for chronic SCI.

Indexed as

CytokinesSpinal Cord InjuriesAnimalsFemaleInflammationMiceMice, KnockoutNeuronsRecovery of FunctionSpinal CordToll-Like Receptor 4CytokinesTlr4 protein, mouseToll-Like Receptor 4cell deathchronic inflammationcytokineextracellular matrix moleculeslocomotor recoveryserotonergic fiber sproutingspinal cord injuryToll-like receptor

Identifiers

PMID38326029
PMCPMC10860514
OpenAlexW4389383657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.